

In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 1-11, 16, 18, 19, and 22-26 without prejudice to their presentation in another application, amend claims 12 and 14, and add new claim 27 as follows:

1-11. (cancelled).

12. (currently amended) A compound selected from:

2-methyl-*N*,1,5-triphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-2-methyl-*N*,5-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-*N*,5-diphenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-2-methyl-*N*,1-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dimethoxyphenyl)-2-methyl-*N*,1-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

2-methyl-1,5-diphenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-2-methyl-5-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-5-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-{{[5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl} piperidine;
 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;
 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;
 1-[(2-methyl-1,5-diphenyl-1*H*-pyrrol-3-yl)carbonyl]piperidine;
 1-{{[1-(4-methoxyphenyl)-2-methyl-5-phenyl-1*H*-pyrrol-3-yl]carbonyl} piperidine;
 1-{{[5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl} piperidine;
 1-{{[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl} piperidine;
 1-{{[5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl} piperidine;
 1-{{[1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl} piperidine; and
 1-{{[5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl} piperidine;
 and where applicable, ~~optical isomers~~, tautomers, stereoisomers and racemates thereof as well as pharmaceutically acceptable salts and solvates thereof.

13. (cancelled).

14. (currently amended) A pharmaceutical composition comprising a compound of ~~any one of claims 1 to~~ claim 12 and a pharmaceutically acceptable adjuvant, diluent or carrier.

15-19. (cancelled).

20. (previously presented) A compound selected from:

Ethyl 1-(4-chlorophenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylate,
 Ethyl 1-(4-methoxyphenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylate,
 Ethyl 5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylate,

Ethyl 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,
Ethyl 5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,
Ethyl 5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylate,
Ethyl 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,
Ethyl 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,

1-(4-Chlorophenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylic acid,
5-(2,4-Dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylic acid,
1-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,
5-(2,4-Dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,
5-(2,4-Dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylic acid,
1-(4-Chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,
and
5-(2,4-Dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid.

21. (previously presented) The composition according to claim 14, comprising an additional agent useful in the treatment of hypertension, hyperlipidaemias, dyslipidaemias, diabetes or atherosclerosis.

22-26. (cancelled).

27. (new) A method of treating obesity in a mammal comprising administering a pharmacologically effective amount of a compound of claim 12 or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, to the mammal in need thereof.